All rights reserved.
Layla Richards. The UK patients were first given the treatment back inafter chemotherapy aggressive cancer means to show results. Now, after two years, both remain cancer-free.
If similar success is seen in future trials, the treatment could offer a cheap and universal way to fight cancers, without needing to tailor T-cells specifically for different patients. The infants, who were 11 months and 16 months when they started the new treatment, had previously undergone chemotherapy to treat leukaemia.
Both treatments failed to show any results, and their parents were told they should prepare for the worst. Unfortunately, the body's T-cells aren't always up to the task of finding and destroying all cancerous cells, especially if they're growing particularly fast.
There have been attempts in the past to improve T-cells' ability specifically seek and destroy cancer cells. But not all patients have enough heathy cells for this to work.
This new process would involve using the blood of donors to create large batches of CAR-T that could be frozen and given out in doses. If successful, the treatment could see use in hospitals all around the world, but only time will tell.
Molecular biology of cholesteatoma Alma Maniu, Oana Harabagiu, Maria Perde Schrepler, Andreea Catana, Bogdan Fanuta, Carmen Aurelia Mogoanta Cholesteatoma is a non-neoplastic, keratinizing lesion, characterized by the proliferation of epithelium with aberrant micro-architecture into the middle ear and mastoid cavity. The exact pathogenic molecular mechanisms behind the formation and propagation of cholesteatoma remain unclear. Immunohistochemical examinations of the matrix and perimatrix have considerably improved the knowledge of cholesteatoma pathogenesis.